These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33499762)

  • 1. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy.
    Gukasyan N; Nayak SM
    Transcult Psychiatry; 2022 Oct; 59(5):652-664. PubMed ID: 33499762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics and Psychotherapy.
    Nayak S; Johnson MW
    Pharmacopsychiatry; 2021 Jul; 54(4):167-175. PubMed ID: 33285578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture.
    Hartogsohn I
    Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.
    Ponomarenko P; Seragnoli F; Calder A; Oehen P; Hasler G
    J Psychopharmacol; 2023 Jul; 37(7):660-678. PubMed ID: 36855289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelics and Evidence-based Psychotherapy: A Systematic Review with Recommendations for Advancing Psychedelic Therapy Research.
    Leone L; McSpadden B; DeMarco A; Enten L; Kline R; Fonzo GA
    Psychiatr Clin North Am; 2024 Jun; 47(2):367-398. PubMed ID: 38724126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Group Therapy.
    Gasser P
    Curr Top Behav Neurosci; 2022; 56():23-34. PubMed ID: 35091980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies.
    Palitsky R; Kaplan DM; Peacock C; Zarrabi AJ; Maples-Keller JL; Grant GH; Dunlop BW; Raison CL
    JAMA Psychiatry; 2023 Jul; 80(7):743-749. PubMed ID: 37256584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement.
    Miceli McMillan R
    J Med Ethics; 2021 Oct; 47(10):701-705. PubMed ID: 33148774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
    Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ
    Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
    Aday JS; Heifets BD; Pratscher SD; Bradley E; Rosen R; Woolley JD
    Psychopharmacology (Berl); 2022 Jun; 239(6):1989-2010. PubMed ID: 35359159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions.
    Cavarra M; Falzone A; Ramaekers JG; Kuypers KPC; Mento C
    Front Psychol; 2022; 13():887255. PubMed ID: 35756295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics and hypnosis: Commonalities and therapeutic implications.
    Lemercier CE; Terhune DB
    J Psychopharmacol; 2018 Jul; 32(7):732-740. PubMed ID: 29938563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
    Dupuis D; Veissière S
    Transcult Psychiatry; 2022 Oct; 59(5):571-578. PubMed ID: 36263513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing placebo: Lessons from psychedelic science.
    Pronovost-Morgan C; Hartogsohn I; Ramaekers JG
    J Psychopharmacol; 2023 Sep; 37(9):866-875. PubMed ID: 37392012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
    Wolff M; Evens R; Mertens LJ; Schmidt C; Beck J; Rutrecht H; Cherniak AD; Gründer G; Jungaberle H
    J Psychopharmacol; 2024 May; 38(5):432-457. PubMed ID: 38742761
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.